ESHG 2019, NIPD Genetics launches PreSENTIA hereditary cancer testing panels
Last week, NIPD Genetics attended the 52nd annual conference of the European Society of Human Genetics (ESHG) where we presented our current products and ...Read More
Trisomy 18 is the second most common and second most severe trisomy1. The condition arises if the egg or the sperm carries an extra chromosome 18, that when combined passes 3 copies of chromosome 18 instead of 2 to the developing baby. Trisomy 18 was first described in 1960 by two groups; John Edwards, whom the disease is named after, and by Smith, Patau, Therman and Inhorn – the team that also described Trisomy 13, Patau syndrome2,3.
Globally, the condition occurs in approximately 1 in 5,000 live births4. The prevalence is greater, estimated to be around 1 in 2,500, but fetal loss during pregnancy and selective terminations after diagnosis due to the severity of the condition are high1,5. Maternal age plays a factor in trisomy 18, and with the mean maternal age having increased during the last 20 years, prevalence rates of trisomy 18 have risen5.
Trisomy 18 is considered less severe than trisomy 13, but the mortality rates are still high with many stillbirths and miscarriages during the first pregnancy months. The chance of spontaneous fetal loss rises from 28% to 41% from weeks 12 to 205. Survival after birth is challenging, with 50% of children sadly dying within their first week of life1,6. Individual symptoms can vary greatly in severity and complexity as 95% of the patients have full trisomy 18. Others have a mosaic form (some cells are trisomic for chromosome 18 and others carry the normal amount) or a partial form (only a section of chromosome 18 is extra)1,6. The latter form arises mostly when the parents unknowingly have a translocation (structural rearrangement of chromosomes) concerning chromosome 187. The risk of recurrence is around 1%, and it primarily applies to translocation carriers. Mosaic and partial forms of trisomy 18 are the ones with the best chances of survival. Patients having these forms are the small percentage that may survive well into adulthood, although with significant developmental and physiological delays. Interestingly, girls with trisomy 18 are found to respond better to treatment and survive longer than boys with trisomy 186,7.
Trisomy 18 is characterized by major and minor abnormalities, affecting all organs and systems. 90% of patients have heart defects, with bone abnormalities, kidney, respiratory, and intestinal problems, resulting in feeding difficulties, also being common4,6,8. Severe developmental delays, delayed growth and distinct characteristics like small jaw, low-set ears, clenched fists, strawberry-shaped head and rocker bottom feet (resembling a rocking chair) may also exist4,6,8. Failure to thrive (gain weight) is seen from the prenatal period, with fetuses affected being smaller than average, and with the mean birth weight being 1700-1800gr4,8.
No specific treatment is available for trisomy 18. Care for trisomy 18 children is usually palliative and conservative, depending on the severity of the symptoms, the parents’ wishes and the doctors’ medical judgement. Respiratory insufficiency and apnea are the major causes of death due to the breathing and feeding problems the patients experience8. Sadly, only around 10% of children with trisomy 18 pass their first birthday, and continuous support and health supervision is needed throughout their lives4,9.
Prenatal detection of trisomy 18 can be achieved through 1st and 2nd trimester screening, and routine ultrasounds as the presence of one or multiple findings are evident. These can include omphalocele (the baby’s organs are outside of the belly, covered in a sac), excess amniotic fluid, very little fetal activity and lower maternal hormone levels. A positive screening test should always be confirmed by a diagnostic test, like chorionic villus sampling (CVS) or amniocentesis. Combined prenatal screening for trisomy 18 is at least 78% accurate10. Non-Invasive Prenatal Testing (NIPT), analyzing the fetal blood through a blood sample taken from the expecting mother from the 10th week of pregnancy, is the most sensitive detecting method, with over 97% accuracy11. Thus, NIPT can reduce the number of unnecessary invasive procedures, and give parents invaluable time to think and research their options regarding clinical management and care.
Several support groups for families with children with trisomy 18 exist, providing precious emotional support and information by sharing experiences, health problems and advances in research. Trisomy 18 is a life-threatening condition, but it is not ‘universally lethal’. Spreading awareness about the condition, the different forms and the variability of symptoms is useful for expecting parents to receive an accurate image of trisomy 18 and be able to make their own informed decisions.
NIPT results, possible next steps and clinical management should always be fully discussed with your healthcare provider. VERACITY and VERAgene both detect Trisomy 18, amongst other common genetic disorders, from the 10th week of pregnancy. To learn more please visit www.nipd.com
Phenylketonuria (PKU) is an inherited, autosomal recessive condition that was first described by Dr.Ivar Asbjørn Følling in 1934 1. Patients with PKU have problems ...Read More
NIPD Genetics will be at the 18th World Congress in Fetal Medicine in Alicante, Spain from 25th to 29th of June. Stop by Booth #12 ...Read More
The NIPD Genetics team will be presenting its ...Read More
NIPD Genetics values your interest in NIPD Genetics, its products and its services. NIPD Genetics takes the protection of your data seriously.
You may contact NIPD Genetics Public Company Ltd at
NIPD Genetics Public Company Ltd
Neas Engomis 31
NIPD Genetics Data Protection Officer can be reached at firstname.lastname@example.org
This page informs you of our policies regarding the collection, use, and disclosure of personal data when you use our Sites and the choices you have associated with that data.
We collect several different types of information for various purposes to provide and improve our Sites and services to you.
While using NIPD Genetics Sites, you may be asked to provide NIPD Genetics certain personally identifiable information that can be used to contact or identify you ("Personal Information"). Personal Information that might be used to identify you includes, but is not limited to:
If you send us a query via our Contact us form, your email address, the content and any follow up emails are retained indefinitely.
We may also collect information how the Sites are accessed and used ("Usage Data"). This Usage Data may include information such as your computer's Internet Protocol address (e.g. IP address), browser type, browser version, the pages of our Sites that you visit, the time and date of your visit, the time spent on those pages, unique device identifiers and other diagnostic data.
Cookies are files with small amount of data which may include an anonymous unique identifier. Cookies are sent to your browser from a website and stored on your device. Tracking technologies also used are beacons, tags, and scripts to collect and track information and to improve and analyze our Sites.
You can instruct your browser to refuse all cookies or to indicate when a cookie is being sent. However, if you do not accept cookies, you may not be able to use some portions of our Sites.
Examples of Cookies we use:
Session Cookies. We use Session Cookies to operate our Sites.
Preference Cookies. We use Preference Cookies to remember your preferences and various settings.
Security Cookies. We use Security Cookies for security purposes.
Visitor behavior cookies. To understand how visitors use and navigate the Sites
Keyword cookies. To understand how visitors discover the Sites.
www.nipd.com uses the collected data for various purposes:
Your information, including personal data, may be transferred to — and maintained on — computers located outside of your province, country or other governmental jurisdiction where the data protection laws may differ than those from your jurisdiction.
If you are located outside Cyprus and choose to provide information to us, please note that we transfer the data, including personal data, to Cyprus and process it there.
NIPD Genetics complies with the protection of personal data regulation and will not sale or trade your personal data.
NIPD Genetics may disclose your personal data in the good faith belief that such action is necessary to:
The security of your data is important to us, but remember that no method of transmission over the Internet, or method of electronic storage is 100% secure. While we strive to use commercially acceptable means to protect your Personal Data, we cannot guarantee its absolute security.
We may employ third party companies and individuals to facilitate, maintain or operate our Sites ("Service Providers"), to provide the SItes on our behalf, to perform service-related services or to assist us in analyzing how our Sites is used.
These third parties have access to your Personal Data only to perform these tasks on our behalf and are obligated not to disclose or use it for any other purpose.
We may use third-party Service Providers to monitor and analyze the use of our Sites.
Google Analytics is a web analytics service offered by Google that tracks and reports website traffic. Google uses the data collected to track and monitor the use of our Service. This data is shared with other Google services. Google may use the collected data to contextualize and personalize the ads of its own advertising network.
For more information on the privacy practices of Google, please visit the Google Privacy & Terms web page
We have no control over and assume no responsibility for the content, privacy policies or practices of any third-party sites or services.
Our Service does not address anyone under the age of 18 ("Children").
We do not knowingly collect personally identifiable information from anyone under the age of 18. If you are a parent or guardian and you are aware that your Children has provided us with Personal Data, please contact us. If we become aware that we have collected Personal Data from children without verification of parental consent, we take steps to remove that information from our servers.